ipilimumab

Shares of Idera Pharmaceuticals Inc. (NASDAQ: IDRA) plunged more than 62% in the extended session Thursday after the biopharmaceutical company said its lead drug candidate Tilsotolimod failed to meet the primary endpoint in a Phase 3 trial for anti-PD-1 refractory advanced melanoma. What Happened:...

Baird initiated coverage of Idera Pharmaceuticals Inc (NASDAQ: IDRA) with an Outperform rating and a $5 price target, suggesting 100-percent upside from current levels. Profiling the company, Baird said Idera is an emerging oncology and rare disease company, focusing on nucleic acid-based therapies...

Idera Pharmaceuticals Inc (NASDAQ: IDRA) is a clinical stage biotech that has recently re-focused its pipeline to focus on oncology, starting with melanoma. The company has seen its share price rise 50 percent in 2017. In March, JMP Securities initiated coverage of the company at Market Outperform...